Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- IMPV -5.5%, ( lowers Q2 guidance citing impacts by extended sales cycles across most geographies and verticals predominantly relating to larger deals)
- FAST -1.8%
Select gold mining stocks trading lower: HMY -2.4%, GOLD -1.8%, AU -1.6%, RGLD -1.6%, CDE -1.4%, ABX -1.1%,NEM -1%, GDX -1%
Other news:
- CYTR -65.3% ( announces results of an analysis of its Phase 3 clinical trial of aldoxorubicin compared to investigator's choice therapy in patients with relapsed or refractory soft tissue sarcomas; study did not show a significant difference between aldoxorubicin and investigator's choice therapy for PFS)
- CKEC -2.5% (AMC Entertainment (AMC) says remains committed to moving forward with plan to acquire Carmike despite announcing it would acquire Odeon & UCI Cinemas Group)
- ALR -2.4% (Alere to initiate voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR monitoring system)
- REG -2.3% (prices 4.35 mln common stock offering; will be no impact to Core Funds from Operations as a result of these one-time charges; however, the combined one-time charges will reduce net income attributable to common stockholders per share and NAREIT FFO/share by ~$0.58 in 3Q16)
- CHRS -1.3% (after closing near highs -- up 25% on the day)
- PANW -1.1% (in sympathy with IMPV guidance)
- TSLA -0.8% (WSJ reported potential SEC investigation)
Analyst comments:
- DRD -5.2% (downgraded to Underweight from Neutral at JP Morgan)
- CBB -1.7% (downgraded to Hold from Buy at Gabelli & Co)
- FIT -1.3% (initiated with a Market Perform at Wells Fargo)
- AWI -1% (downgraded to Sell from Neutral at Goldman)
- VOD -0.9% (downgraded to Neutral from Buy at Citigroup)